American College of Neuropsychopharmacology

From Powerbase
Revision as of 00:33, 31 January 2010 by Marisa de Andrade (talk | contribs) (New page: {{Template:Pharma_Portal_badge}} The '''American College of Neuropsychopharmacology''' (ACNP) is the 'nation's premier professional society in brain, behavior, and psychopharmacology ...)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Pharma badge.jpg This article is part of the Pharma_Portal project of Spinwatch.

The American College of Neuropsychopharmacology (ACNP) is the 'nation's premier professional society in brain, behavior, and psychopharmacology research.' It describes itself as a non-profit, professional society dedicated to advancing the scientific understanding of and the dissemination of knowledge about neuropsychiatric disorders in order to advance their prevention and treatment.' [1]

Policies on Financial Disclosure & Conflicts of Interest (COI)

The ACNP has 'historically provided a venue at which the best scientists from academia, government, and industry have gathered to share, discuss, and debate their research'. To facilitate this, the College is funded by 'membership dues, royalties from publication sales, meeting registration fees, and grants from corporations or governmental agencies.'[2] It aims to eradicate potential real and perceived COIs by using 'firewalls' to 'protect the integrity of College operations and to prevent the influence of financial sponsors from penetrating decision making processes of the College.' [3]

Funding

On its website, the ACNP reports that in 2009 it received $3,264,003.00 in revenue from: corporate fees (30%); annual meetings registration (26%); industry grants (17%); royalty income (15%); member dues (26%); subscription income (3%); management fee income (1%); and other sources(1%).

Supporting corporation sustaining fees ranging from $25,000 to $50,000 came from: Abbott Laboratories; AstraZeneca; Bristol-Myers Squibb Company; Dainippon Sumitomo Pharmaceuticals; Eli Lilly and Company; Forest Pharmaceuticals; GlaxoSmithKline; H Lundbeck A/S; Hoffman-LaRoche; Janssen Pharmaceutica; Johnson & Johnson; Memory Pharmaceuticals; Merck; Novartis; Otsuka America Pharmaceuticals; Pfizer; Sanofi-Aventis; Schering-Plough; Sepracor, Inc.; Shire Pharmaceuticals; Solvay; Takeda Pharmaceuticals; Targacept, Inc.; and Wyeth.

Alkermes; AstraZeneca; Eli Lilly & Company; H Lundbeck A/S; Merck; Novartis; Ortho-McNeil Janssen; Otsuka America Pharmaceuticals; Pfizer; Sanofi-Aventis; and Wyeth gave financial support (ranging from $15,000 to $71,720) for specific projects.[4]

Contact

Address:
American College of Neuropsychopharmacology
545 Mainstream Drive, Suite 110
Nashville, TN 37228
Phone: 615-324-2360
Email: acnp@acnp.org
Website: http://www.acnp.org/default.aspx

Notes

  1. ACNP.ACNP:About us. Accessed 30 January 2010.
  2. ACNP.ACNP:About us. Accessed 30 January 2010.
  3. ACNP.ACNP Financial Disclosure & COI Firewalls Accessed 30 January 2010.
  4. ACNP. ANCP Financial Disclosure & COI Firewalls. Accessed 30 January 2010.